News | Ablation Systems | May 11, 2016

Cardiac Ablation Does Not Reduce Atrial Fibrillation Risk for Wolff-Parkinson-White Patients

Study presented at HRS finds treating extra pathway has no impact on afib risk, regardless of age

May 11, 2016 — Patients with Wolff-Parkinson-White syndrome who receive catheter ablation to cure their abnormal heart rhythms are just as likely as non-ablated patients to develop atrial fibrillation no matter what age they receive ablation, according to a new study.

The study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City also found that Wolff-Parkinson-White syndrome is a long-term cause of atrial fibrillation in addition to traditional risk factors such as obesity, high blood pressure, sedentary lifestyles and sleep apnea.

Wolff-Parkinson-White is a syndrome that results in an abnormal electrical pathway from the upper to the lower heart chambers. Patients with the syndrome can experience rapid abnormal heart rates when electricity bypasses the normal electrical system of the heart and uses the extra pathway.

Researchers at the Intermountain Medical Center Heart Institute initially set out to discover if catheter ablation reduces the long-term risk of atrial fibrillation and whether the patients' age at the time of the procedure affected their risk.

Their study consisted of previously collected data from three different groups: 872 Wolff-Parkinson-White patients who received ablation treatment between ages 22 and 57; 1,461 patients who were treated with medication; and 11,175 people who didn't have the syndrome.

The researchers found that no matter at which age an ablation is performed, adult patients with Wolff-Parkinson-White continue to have a life-long, significant risk of atrial fibrillation.

"When a lot of physicians encounter patients with Wolff-Parkinson-White and atrial fibrillation, they believe that if the accessory or extra pathway is treated and cured, then the risk of atrial fibrillation is removed," said Intermountain Medical Center Heart Institute cardiologist Jared Bunch, M.D., lead researcher of the study. "Our findings unfortunately do not confirm that belief and suggest otherwise."

The Intermountain Medical Center Heart Institute research team presented results of their study at the Heart Rhythm Society's 2016 Scientific Session, May 4-7, in San Francisco.

Catheter ablation is a technique that can cure the abnormal heart rhythms by cauterizing or freezing that extra pathway.

Atrial fibrillation is a common and irregular and rapid heart rate that occurs when the left ventricle stiffens to counteract high blood pressure while the left atrium dilates in response to higher pressures.

Blood clots commonly form in patients with atrial fibrillation, which makes it one of the most common causes of strokes.

Bunch said it's possible that Wolff-Parkinson-White patients also have an atrial myopathy, or abnormal heart muscle, that leads to long-term atrial fibrillation risk — independent of the extra pathway. He says close follow-up throughout the lives of patients with atrial fibrillation can help prevent risk of stroke.

The other members of the Intermountain Medical Center Heart Institute research team included Heidi May, Ph.D., MSPH; Tami Bair, RN; Brian Crandall, M.D.; Michael Cutler, DO, Ph.D., Victoria Jacobs, NP; Charles Mallender, M.D.; Jeffrey Osborn, M.D.; Peter Weiss, M.D., and John Day, M.D.

Intermountain Medical Center is the flagship facility for the Intermountain Healthcare system, which is based in Salt Lake City.

For more information: www.hrsonline.org

Related Content

First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during...
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Overlay Init